Percutaneous transluminal coronary angioplasty: Comparison of arterial vs. venous activated clotting time

Catheterization and Cardiovascular Diagnosis

Volumn 37, Issue 2, 1996, Pages 140-144

  Pesola, Gene R ^a,b   Johnson, Audrey ^a   Pesola, David A ^a  

^a Marquette General Hospital   (United States)

^b ST VINCENT S HOSPITAL   (United States)

Author keywords

ACT; arterial vs. venous; porcine heparin; PTCA

Indexed keywords

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; FEMALE; HEPARINIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; TRANSLUMINAL CORONARY ANGIOPLASTY; VENOUS BLOOD;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BLOOD COAGULATION; CORONARY DISEASE; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; WHOLE BLOOD COAGULATION TIME;

EID: 0030048441     PISSN: 00986569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0304(199602)37:2<140::AID-CCD7>3.0.CO;2-D     Document Type: Article

References (23)

1. Rath B, Bennett DH: Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. Br Heart J 63:18-21, 1990.
2. Hattersley P: Activated coagulation time of whole blood. JAMA 196:150-154, 1966.
3. Hattersley PG: The activated coagulation time of whole blood (ACT). Progress report. Am J Clin Pathol 66:899-903, 1976.
4. Hill JD, Dontigny L, de Leval M, Mielde CH: A simple method of heparin management during extracorporeal circulation. Ann Thorac Surg 17:129-134, 1974.
5. Schriever HG, Epstein SE, Mintz MD: Statistical correlation and heparin sensitivity of activated partial thromboplastin time, whole blood coagulation time, and an automated coagulation time. Am J Clin Pathol 60:323-329, 1973.
6. Reiner JS, Coyne KS, Lundergon CF, Ross AM: Bedside monitoring of heparin therapy: Comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn 32:49-52, 1994.
7. Stenberg S, Berg E, Albrechtsen OK: Heparin levels and activated clotting time (ACT) during open heart surgery. Scand J Haematol 26:281-284, 1981.
8. Grill HP, Spero JE, Granato JE: Comparison of activated partial thromboplastin time to activated clotting time for adequacy of heparin anticoagulation just before percutaneous transluminal coronary angioplasty. Am J Cardiol 71:1219-1220, 1993.
9. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB: Adequate heparinization during PTCA: Assessment using activated clotting times. Cathet Cardiovasc Diagn 18:206-209, 1989.
10. Dougherty KG, Gaos CM, Bush HS, Leachman R, Ferguson JJ: Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 26:260-263, 1992.
11. Bull BS, Korpman RA, Huse WM, Briggs BD: Heparin therapy during extracorporeal circulation I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 69:674-684, 1975.
12. Avendano A, Ferguson JJ: Comparison of hemochron and hemotec activated coagulation time target values during percutaneous transluminal coronary angioplasty. Interventional Cardiol 23: 907-910, 1994.
13. Blumenthal RS, Brinker JA: The acts of coronary angioplasty. Cathet Cardiovasc Diagn 34:6-7, 1995.
14. Warner MF, Mian MS, Missri JC: Activated clotting-time variability in patients undergoing coronary angioplasty. Clin Cardiol 17:372-374, 1994.
15. Jain AK, McMahon FG, Ryan JR: Comparison of anticoagulant activity of three preparations of heparin. Curr Ther Res 22:427-437, 1977.
16. Loganathan D, Wang HM, Mallis LM, Linhardt RJ: Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources. Biochemistry 29:4362-4368, 1990.
17. Linhardt RJ, Ampofo SA, Fareed J, Hoppenstadt D, Mulliken JB, Folkma S: Isolation and characterization of human heparin. Biochemistry 31:12441-12445, 1992.
18. Vaitkus PT, Herrmann HC, Laskey WK: Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty. Am Heart J 124: 1-8, 1992.
19. Bowers J, Ferguson JJ: The use of activated clotting times to monitor heparin therapy during and after interventional procedures. Clin Cardiol 17:357-361, 1994.
20. Narins CR, Hilleglass WB, Nelson CL, Harrington RA, Phillips HR, Stach RS, Califf RM: Activated clotting time predicts abrupt closure risk during angioplasty. J Am Coll Cardiol 6:470, 1994.
21. Harrington RA, Leimberger JD, Berdan L, Topol EJ, Califf RM: The ACT index: A method for stratifying likelihood of success and risk of acute complications in coronary intervention. Circulation 88:1-208, 1993.
22. Cipolle RJ, Seifert RD, Neilan BA, Zaske DE, Haus E: Heparin kinetics: Variables related to disposition and dosage. Clin Pharmacol Ther 29:387-393, 1981.
23. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S: The weight-based heparin dosing nomogram compared with a standard care nomogram: A randomized control trial. Ann Intern Med 119:874-881, 1993.